..

I am ONE of the authors of the study. This "retrospective" study looks for ASSOCIATION, not causality. Now that we have randomized clinical trials, we can say with certainty that IVERMECTIN DOES NOT WORK AT ALL FOR COVID. I recommend to read the conclusions of the abstract.

— Jose Gonzales Zamora (@JoseGonzalesZa1) March 3, 2022

..

Treatment with Ivermectin Is Associated with Decreased Mortality in COVID-19 Patients: Analysis of a National Federated Database

https://t.co/1qe3ODQZhl

— KittyPooh (@KittyPo80176717) March 3, 2022

International Journal of Infectious Diseases

Volume 116, Supplement, March 2022, Page S40

PS05.04 (947)Treatment with Ivermectin Is Associated with Decreased Mortality in COVID-19 Patients: Analysis of a National Federated Database

Author links open overlay panelI.Efimenko¹

S.Nackeeran²S.Jabori³J.A. GonzalezZamora⁴S.Danker³D.Singh¹

¹University of Miami, Plastic Surgery, Miami, United States²University of Miami, Urology, Miami, United States³University of Miami, Plastic Surgery, Miami, United States⁴University of Miami, Infectious Diseases, Miami, United States

Available online 28 February 2022, Version of Record 28 February 2022.

Purpose

To evaluate the difference in mortality of patients treated with ivermectin vs patients treated with remdesivir with COVID-19 in United States using TriNetX Research network, a federated EMR network of over 44 healthcare organizations and 68 million patients from US, from 2009-2021.

Methods & Materials

We retrospectively identified adults (≥18 years) with a recorded COVID-19 infection between January 1, 2020 and July 11, 2021. We compared those with recorded use of ivermectin, but not remdesivir, against those with recorded use of remdesivir, but not ivermectin. We controlled for the following demographics, comorbidities, and treatments that may affect COVID-19 survival outcomes: age, gender, race, ethnicity, nicotine use diabetes mellitus, obesity, chronic lower respiratory disease, ischemic heart diseases, tocilizumab, glucocorticoids, or ventilator use. We measured association with mortality as the primary outcome, with significance assessed at p<0.05.

Results

There were a total of 1,761,060 possible COVID-19 patients based on ICD-10 diagnostic terms and confirmatory lab results. Prior to controlling, our analysis yielded 41,608 patients who had COVID-19 resulting in two unique cohorts that were treated with either ivermectin (1,072) or remdesivir (40,536). Within the ivermectin cohort, average age was 51.9 + 17.8 years, 43% were male, 60% had glucocorticoids and 1% required ventilator support. In the remdesivir cohort, average age was 62.0 + 16.0 years, 54% were male, 64% had glucocorticoids and 2% required ventilator support. After using propensity score matching and adjusting for potential confounders, ivermectin was associated with reduced mortality vs remdesivir (OR 0.308, 95% CI (0.198,0.479)),Risk Difference -5.224%, CI (-7.079%,-3.369%), p <0.0001.

Conclusion

Ivermectin use was associated with decreased mortality in patients with COVID-19 compared to remdesivir. To our knowledge, this is the largest association study of patients with COVID-19, mortality and ivermectin. Further double-blinded placebo-controlled RCTs with large samples are required for definite conclusion. In the future, if more publications are published with the similar result to the current analyses, the certainty of evidence will increase.

https://www.sciencedirect.com/science/article/pii/S1201971221009887

..

..

New embarrassingly bad study of ivermectin is a textbook example of “confounding by indication”

In short a retroactive database review found that people w/ COVID did worse if given remdesivir (only given to sick inpatients) than ivermectin (only given to well outpatients)🤔
1/ pic.twitter.com/f76tBBmuVl

— Nick Mark MD (@nickmmark) March 3, 2022

The methods are weird.

They found 1.7 million people w/ COVID. Out of this group they identified 1,072 who received ivermectin (not exactly widely used) & 40k who received remdesivir

The groups were very dissimilar: IVM was 10 yrs younger. They don’t report any comorbidities
3/ pic.twitter.com/RI2n1orRcI

— Nick Mark MD (@nickmmark) March 3, 2022

The authors are interesting…

The first two are medical students, the 3rd is a plastic surgery resident.
(Nothing wrong with this, though it is weird for the MS not to be affiliated w/ SOM)

The fifth & sixth authors are plastic surgeons. Neither has expertise in ID or COVID
5/ pic.twitter.com/wIu7SL1hrI

— Nick Mark MD (@nickmmark) March 3, 2022

All of this makes me wonder – did the authors all even read/approve this abstract?

Did the peer reviewers think it was odd that plastic surgeons were doing research on ivermectin for COVID?
7/

— Nick Mark MD (@nickmmark) March 3, 2022

Bottom line:
-this abstract of a retrospective review is fatally flawed due to the confounder of hospitalization (+more). There is no evidence that ivermectin reduces mortality
-it won’t stop fringe docs cashing in on selling ivermectin from promoting this “massive study”
9/9 pic.twitter.com/fJqTH3WCWP

— Nick Mark MD (@nickmmark) March 3, 2022

Ah yes, Pierre Kory also doesn't understand endogeneity… or at least is willfully ignorant of it.

— Cal (@ChampCaI) March 3, 2022

..